Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?

E-ISSN： 1097-0142|120|11|1604-1607

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.11, 2014-06, pp. : 1604-1607

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

By Garcia Jorge A. Hudes Gary R. Choueiri Toni K. Stadler Walter M. Wood Laura S. Gurtler Jayne Bhatia Shailender Joshi Adarsh Hozak Rebecca R. Xu Yihuan Schwartz Jonathan D. Thompson John A.

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1647-1655

Blackwell Publishing

Access to resources Recommend Favorite

Axitinib for the Management of Metastatic Renal Cell Carcinoma

By Escudier Bernard

Drugs in R&D, Vol. 11, Iss. 2, 2011-06 ,pp. : 113-126

Adis International

Access to resources Recommend Favorite

Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma

Current Clinical Pharmacology, Vol. 6, Iss. 3, 2011-08 ,pp. : 189-198

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Immunotargets in Metastatic Renal Cell Carcinoma

Current Drug Targets, Vol. 17, Iss. 7, 2016-06 ,pp. : 771-776

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults

By Pal Sumanta K.

Drugs & Aging, Vol. 28, Iss. 8, 2011-08 ,pp. : 635-649

Adis International

Access to resources Recommend Favorite